000			04122nam a2200337 i 4500
999			_c398777 _d398777
001			398777
003			ES-MaUEC
005			20240311134543.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			240104s2024 sz | o |||| 0|eng d
020			_a9783031421082
024	7		_a10.1007/978-3-031-42108-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQR46 _b2024 EB
245	0	0	_aUpdates on Clostridioides difficile in Europe : _bAdvances in Microbiology, Infectious Diseases and Public Health _nVolume 18 _cedited by Paola Mastrantonio, Maja Rupnik
250			_a2nd ed. 2024
264		1	_aCham _bSpringer International Publishing _c2024
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aAdvances in Microbiology, Infectious Diseases and Public Health _x2365-2683 _v1435
505	0		_aEconomic burden of Clostridioides difficile infection in European countries -- The need for European surveillance of CDI.-Diagnostic guidance for C. difficile infections -- European practice for CDI treatment -- Faecal microbiota transplantation as emerging treatment in European countries 2.0 -- Probiotics for prevention and treatment of Clostridioides difficile infection -- Immunization strategies against Clostridioides difficile -- Ribotypes and new virulent strains across Europe -- Antibiotic resistances of Clostridioides difficile -- Comparative genomics of Clostridioides difficile -- An updated view on the cellular uptake and mode-of-action of Clostridioides difficile toxins -- Clostridioides difficile biofilm -- Clostridioides difficile sporulation -- Membrane vesicles of C.difficile and other Clostridial species -- Non-human C.difficile reservoirs and sources: animals,food, environment -- The ESCMID Study Group for Clostridioides difficile : history, role and perspectives.
520			_aThis fully updated second edition outlines the currently available clinical, epidemiological and experimental data on Clostridioides difficile infections(CDI) with special emphasis on studies and results achieved in Europe. The incidence and severity of CDI has increased significantly over the last decade, and the book explains why C. difficile, recently reclassified as Clostridioides difficile, remains a significant challenge, also from economic perspective, to health care systems all over the world. The different reservoirs of this ubiquitous microorganism are reviewed as well as the different factors contributing to its virulence, such as toxins and biofilm formation. The rapid evolution of antibiotic resistance is clearly a concern and in a specific way can influence the CDI epidemiology. Additionally, new emerging strains and comparative genomics studies are taken into consideration for their relevance from epidemiological and evolutionary point of view. The book also gives an overview on diagnostics, therapy and surveillance, all of which are still challenging. Therefore, a closer look is taken on the effect of probiotics as an alternative to antibiotics, for prevention and treatment of CDI. Fecal transplantation from healthy donors, passive immunotherapies and vaccines for patients with recurrences are also discussed in dedicated chapters. New topics included sporulation and membrane vesicles in C. difficile. The book closes with a summary of the history and the achievements of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Clostridium difficile (ESGCD) written by the current and past presidents of the Society. It is the aim of this book to raise awareness on CDI and to disseminate updated information on its prevention, diagnosis and treatment.
988			_aSpringer_BiomedLife_2024
650		7	_2embne _9138684 _aMicrobiología
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-42108-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b03/2024 _dz _eb _zSI